Adopting a strategic approach to managing PV activities for the mature portfolio
One approach many adopt is to work with outsourcing partners to support the regulatory (RA), pharmacovigilance (PV), and quality activities (QA) that are crucial to keeping the product on global markets while reducing the product maintenance costs involved.
Thinking global, acting local with pharmacovigilance expertise
Additionally, companies with products on the market in Europe must follow dedicated European pharmacovigilance regulations, e.g. they must have fully compliant and functional PV systems, overseen by a Qualified Person for Pharmacovigilance (QPPV).2
Rather than having full-time personnel on the ground in multiple global markets, companies often turn to outsourcing partners to support crucial regulatory and safety activities from a central hub, while also ensuring on-the-ground support for local activities.
Adopting a harmonized, forward-looking approach to PV
It also helps companies achieve strategic oversight of all pharmacovigilance responsibilities and paves the way for expanding into new markets without the need to bring on additional staff in those regions.
Another key consideration for companies is the ability to leverage digital innovation tools, such as artificial intelligence, to support key safety activities such as signal management. At the same time, however, investing in digital capabilities is cost-intensive and hard to justify for mature products. Outsourcing management of the mature portfolio, including essential PV activities, to a partner with digital capabilities and expertise gives biopharma companies access to those solutions, as and where it makes business sense.
Reducing complexity with an integrated PV approach
In one example, a German biopharmaceutical organization needed a comprehensive outsourced solution for PV tasks for its large portfolio of marketing authorizations. Key requirements included fully outsourced pharmacovigilance system administration, including a fully validated safety database, support for all operational PV activities, and effective coordination of its worldwide network of strategic partners.
The company turned to Cencora for a PV system that would consolidate its pharmacovigilance responsibilities under a single provider, serving multi-territory needs and providing strategic oversight. The partnership resulted in reduced complexity and streamlined safety activities – from management of the PV system to end-to-end pharmacovigilance oversight to audit and inspection readiness to ongoing intelligence for all drug safety and cross-functional issues.
Adopting an adaptable approach to pharmacovigilance outsourcing
For example, a U.S.-based company may seek a partner to support the QPPV requirements in Europe, leaving that partner to manage PV activities there. Alternatively, if the company has a European office to support central activities (such as the QPPV) but has no local expertise, it might seek a partner to cover local affiliate services rather than having to employ local contact personnel for each market to carry out local literature screening and perform local risk assessments, case intakes, and other local activities. As needs grow and as the portfolio matures, companies may choose to extend the outsourcing engagement to other service lines.
The emphasis is to seek support where it makes greatest strategic sense, such as where the company lacks resources to manage essential activities or where local expertise is required.
As products mature and the company’s focus shifts to new product development, the opportunity to expand the outsourcing relationship to achieve global holistic support across PV, regulatory, and quality can be leveraged – how, when and where it makes strategic business sense.
About the author:
Connect with our team
Sources
1. Big Pharma race to snap up biotech assets as $170 billion patent cliff looms, CNBC, 7 January 2026. Accessed 12 March 2026. https://www.cnbc.com/2026/01/07/big-pharma-race-to-snap-up-biotech-assets-as-170-billion-patent-cliff-looms.html
2. Pharmacovigilance system: questions and answers, EMA. Accessed 12 March 2026. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/pharmacovigilance-system-questions-answers
Related resources
[EXEMPLE DE PLEINS FEUX - S’IL VOUS PLAÎT LIRE]
S’IL VOUS PLAÎT, REMPLACEZ CE PROJECTEUR PAR UN ÉLÉMENT DE CONTENU APPROPRIÉ !
Modifiez le contenu associé à ce module en sélectionnant l’un des éléments de contenu Full Image Spotlight dans /Paramètres du site Web/Contenu partagé/Bannières globales
Cencora.com fournit des traductions automatiques pour faciliter la lecture du site Web dans des langues autres que l’anglais. Pour ces traductions, des efforts raisonnables ont été faits pour fournir une traduction précise, cependant, aucune traduction automatique n’est parfaite et n’est pas destinée à remplacer les traducteurs humains. Ces traductions sont fournies en tant que service aux utilisateurs de Cencora.com et sont fournies « en l’état ». Aucune garantie d’aucune sorte, expresse ou implicite, n’est donnée quant à l’exactitude, la fiabilité ou l’exactitude de ces traductions effectuées de l’anglais vers une autre langue. Certains contenus (tels que les images, les vidéos, Flash, etc.) peuvent ne pas être traduits avec précision en raison des limitations du logiciel de traduction.
Toute divergence ou différence créée lors de la traduction de ce contenu de l’anglais vers une autre langue n’est pas contraignante et n’a aucun effet juridique pour la conformité, l’application ou toute autre fin. Si des erreurs sont identifiées, veuillez nouscontacter. Si vous avez des questions sur l’exactitude des informations contenues dans ces traductions, veuillez vous référer à la version anglaise de la page.
